scispace - formally typeset
Journal ArticleDOI

Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract

Reads0
Chats0
TLDR
Adjunctive treatment with Withaferin A (WA) reduced myeloid cell-mediated immune suppression, polarized immunity toward a tumor-rejecting type 1 phenotype, and may facilitate the development of anti-tumor immunity.
Abstract
Myeloid cells play a crucial role in tumor progression. The most common tumor-infiltrating myeloid cells are myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAMs). These cells promote tumor growth by their inherent immune suppressive activity which is enhanced by their cross-talk. The root extract of the plant Withania somnifera (Ashwagandha) (WRE) has been reported to reduce tumor growth. HPLC analysis identified Withaferin A (WA) as the most abundant constituent of WRE and led us to determine whether the anti-tumor effects of WRE and WA involve modulating MDSC and TAM activity. A prominent effect of MDSC is their production of IL-10 which increases upon cross-talk with macrophages, thus polarizing immunity to a pro-tumor type 2 phenotype. In vitro treatment with WA decreased MDSC production of IL-10 and prevented additional MDSC production of IL-10 generated by MDSC–macrophage cross-talk. Macrophage secretion of IL-6 and TNFα, cytokines that increase MDSC accumulation and function, was also reduced by in vitro treatment with WA. Much of the T-cell suppressive activity of MDSC is due to MDSC production of reactive oxygen species (ROS), and WA significantly reduced MDSC production of ROS through a STAT3-dependent mechanism. In vivo treatment of tumor-bearing mice with WA decreased tumor weight, reduced the quantity of granulocytic MDSC, and reduced the ability of MDSC to suppress antigen-driven activation of CD4+ and CD8+ T cells. Thus, adjunctive treatment with WA reduced myeloid cell-mediated immune suppression, polarized immunity toward a tumor-rejecting type 1 phenotype, and may facilitate the development of anti-tumor immunity.

read more

Citations
More filters
Journal ArticleDOI

Broad targeting of angiogenesis for cancer prevention and therapy

TL;DR: 10 important aspects of tumor angiogenesis and the pathological tumor vasculature which would be well suited as targets for anti-angiogenic therapy are identified and 10 plant-derived compounds could be combined to constitute a broader acting and more effective inhibitory cocktail at doses that would not be likely to cause excessive toxicity.
Book ChapterDOI

Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

TL;DR: The history and identification of M DSCs, the role of inflammation and intracellular signaling events governing MDSC accumulation and suppressive activity, immune-suppressive mechanisms utilized by MDSCs, and recent therapeutics that target MDScs to enhance antitumor immunity are described.
Journal ArticleDOI

Myeloid derived suppressor cells—An overview of combat strategies to increase immunotherapy efficacy

TL;DR: Effective mono- or multimodal-therapies that target MDSCs for the benefit of cancer treatment are described.
Journal ArticleDOI

HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells

TL;DR: HMGB1 promotes the development of MDSCs from bone marrow progenitor cells, contributing to their ability to suppress antigen-driven activation of CD4(+) and CD8(+) T cells, and increases MDSC-mediated production of IL-10, enhanced crosstalk between MDSCS and macrophages, and facilitated the ability of M DSCs to downregulate expression of the T-cell homing receptor L-selectin.
References
More filters
Journal ArticleDOI

Myeloid-derived suppressor cells as regulators of the immune system.

TL;DR: The origin, mechanisms of expansion and suppressive functions of MDSCs, as well as the potential to target these cells for therapeutic benefit are discussed.
Journal ArticleDOI

Coordinated regulation of myeloid cells by tumours

TL;DR: This work considers myeloid cells as an intricately connected, complex, single system and focuses on how tumours manipulate the myeloids system to evade the host immune response.
Journal ArticleDOI

NF-kappaB: linking inflammation and immunity to cancer development and progression.

TL;DR: The hypothesis is put forward that activation of nuclear factor-κB by the classical, IKK-β (inhibitor-of-NF-β kinase-β)-dependent pathway is a crucial mediator of inflammation-induced tumour growth and progression, as well as an important modulator of tumour surveillance and rejection.
Journal ArticleDOI

NF-κB in cancer: from innocent bystander to major culprit

TL;DR: Recent evidence indicates that NF-κB and the signalling pathways that are involved in its activation are also important for tumour development.
Journal ArticleDOI

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

TL;DR: The characterization and suppressive mechanisms used by myeloid-derived suppressor cells to block tumor immunity are reviewed and the mechanisms by which inflammation promotes tumor progression through the induction of MDSC are described.
Related Papers (5)